Role of KAISO and P120 complex in lymphoid leukemia

2020 Fiscal Year Final Research Report

• Project/Area Number: 19K23921
• Research Category: Grant-in-Aid for Research Activity Start-up
• Allocation Type: Multi-year Fund
• Review Section: 0901:Oncology and related fields
• Research Institution: Sapporo Medical University
• Principal Investigator: Horiguchi Hiroto 札幌医科大学, 医学部, 研究員 (70634674)
• Project Period (FY): 2019-08-30 – 2021-03-31
• Keywords: KAISO / リンパ性白血病

Outline of Final Research Achievements

We purchased acute leukemia cell lines (BALL-1, HAL-01, NALM-6, TALL, MOLT-4, and Jurkat). They were cultured and their RNAs were extracted by using TRIzol.
Reverse transcription quantitative polymerase chain reaction (RT-qPCR) revealed that KAISO mRNAs of BALL-1 and HAL-01 were significantly decreased than normal B cell and KAISO mRNAs of TALL, MOLT-4, and Jurkat were significantly decreased than normal T cell. Moreover, Catenin delta-1 mRNAs of all B cell leukemia lines and T cell leukemia cell lines were significantly decreased than normal B cell and T cell, respectively.

Free Research Field

血液

Academic Significance and Societal Importance of the Research Achievements

急性リンパ性白血病におけるKAISO mRNAの発現は、多くの細胞株で正常B細胞、正常T細胞と比較し、優位に低下していることが明らかとなったが、その一部の細胞株では低下していなかった。一方で、KAISOの関連分子であるCatenin delta-1のｍRNAの急性リンパ球性白血病株での発現は、正常のB細胞とT細胞と比較し、すべての白血病細胞株で有意に低下していた。このことは、KAISOやCatenin delta-1が治療の標的となりえることが、期待される。